IBN Coverage Initiated for Nutriband Inc.
25 avr. 2024 07h00 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, April 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Nutriband Inc. (NASDAQ: NTRB), a pharmaceutical company with a specific focus on transdermal technologies, today announces it has selected...
Antispasmodics Drugs: Global Market Analysis and Forecast 2018-2033 Featuring Daiichi Sankyo Company, Fresenius Kabi, Hikma Pharma, Johnson & Johnson Services, Pfizer, and Other Key Players
24 avr. 2024 04h10 HE
|
Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Antispasmodics Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The antispasmodics drugs market size has...
European and USA Pharmaceutical Directory 2024: Indispensable Guide for Key Decision-makers
15 avr. 2024 09h04 HE
|
Research and Markets
Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "European and USA Pharmaceutical Directory 2024" directory has been added to ResearchAndMarkets.com's offering.The European & USA Pharmaceutical...
Global Directory Unveils Top 1,000 Pharmaceutical and Biotechnology Companies for 2024
15 avr. 2024 09h02 HE
|
Research and Markets
Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Major Pharmaceutical Companies 2024" report has been added to ResearchAndMarkets.com's offering. In an era of rapid technological advancements and...
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
11 avr. 2024 08h00 HE
|
Processa Pharmaceuticals, Inc.
NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile NGC-Cap holds potential for improved efficacy in more...
Global Convalescent Plasma Therapy Market to Grow at a CAGR of 11.8% from 2023 to 2024
28 mars 2024 18h03 HE
|
Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Convalescent Plasma Therapy Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Market InsightsThe global market...
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
26 févr. 2024 08h30 HE
|
Lixte Biotechnology Holdings, Inc.
Agreement Focuses on Combining LIXTE’s LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and...
Top 5 Growth Opportunities for the Pharmaceutical Industry in 2024
23 févr. 2024 04h38 HE
|
Research and Markets
Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Top 5 Growth Opportunities for the Pharmaceutical Industry, 2024" report has been added to ResearchAndMarkets.com's offering. In 2024, the life...
Pharmaceutical Industry in South Africa: New Research Highlights Opportunities Amidst Economic Challenges
16 févr. 2024 04h29 HE
|
Research and Markets
Dublin, Feb. 16, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Industry in South Africa 2023" report has been added to ResearchAndMarkets.com's offering. Recent analysis of the South African...
Fabry Disease Treatment Market: Comprehensive Insights and Growth Projections for 2024-2030
14 févr. 2024 16h36 HE
|
Research and Markets
Dublin, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The "Global Fabry Disease Treatment Market by Treatment Type (Chaperone Treatment, Enzyme Replacement Therapy, Organ-Specific Treatment), Drugs (Agalsidase...